These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 25984235)
1. Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration. Alvarez Palomo AB; McLenachan S; Chen FK; Da Cruz L; Dilley RJ; Requena J; Lucas M; Lucas A; Drukker M; Edel MJ Fibrogenesis Tissue Repair; 2015; 8():9. PubMed ID: 25984235 [TBL] [Abstract][Full Text] [Related]
2. Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD). Fields M; Cai H; Gong J; Del Priore L Cells; 2016 Dec; 5(4):. PubMed ID: 27941641 [TBL] [Abstract][Full Text] [Related]
3. Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization. Hazim RA; Karumbayaram S; Jiang M; Dimashkie A; Lopes VS; Li D; Burgess BL; Vijayaraj P; Alva-Ornelas JA; Zack JA; Kohn DB; Gomperts BN; Pyle AD; Lowry WE; Williams DS Stem Cell Res Ther; 2017 Oct; 8(1):217. PubMed ID: 28969679 [TBL] [Abstract][Full Text] [Related]
4. Stem cell based therapies for age-related macular degeneration: The promises and the challenges. Nazari H; Zhang L; Zhu D; Chader GJ; Falabella P; Stefanini F; Rowland T; Clegg DO; Kashani AH; Hinton DR; Humayun MS Prog Retin Eye Res; 2015 Sep; 48():1-39. PubMed ID: 26113213 [TBL] [Abstract][Full Text] [Related]
5. Differentiation of human pluripotent stem cells to retinal pigmented epithelium in defined conditions using purified extracellular matrix proteins. Rowland TJ; Blaschke AJ; Buchholz DE; Hikita ST; Johnson LV; Clegg DO J Tissue Eng Regen Med; 2013 Aug; 7(8):642-53. PubMed ID: 22514096 [TBL] [Abstract][Full Text] [Related]
7. The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation. Palomo AB; Lucas M; Dilley RJ; McLenachan S; Chen FK; Requena J; Sal MF; Lucas A; Alvarez I; Jaraquemada D; Edel MJ J Clin Med; 2014 Apr; 3(2):373-87. PubMed ID: 26237380 [TBL] [Abstract][Full Text] [Related]
8. [Development of Cellular and Tissue-based Products for Retinal Regenerative Medicine]. Osakada F Yakugaku Zasshi; 2017; 137(1):23-29. PubMed ID: 28049891 [TBL] [Abstract][Full Text] [Related]
9. Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD). Surendran H; Rathod RJ; Pal R Methods Mol Biol; 2019; 2045():283-298. PubMed ID: 29896658 [TBL] [Abstract][Full Text] [Related]
10. Using induced pluripotent stem cell-derived conditional medium to attenuate the light-induced photodamaged retina of rats. Chang HM; Hung KH; Hsu CC; Lin TC; Chen SY J Chin Med Assoc; 2015 Mar; 78(3):169-76. PubMed ID: 25557467 [TBL] [Abstract][Full Text] [Related]
11. Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling. Requena J; Alvarez-Palomo AB; Codina-Pascual M; Delgado-Morales R; Moran S; Esteller M; Sal M; Juan M; Boronat Barado A; Consiglio A; Bogle OA; Wolvetang E; Ovchinnikov D; Alvarez I; Jaraquemada D; Mezquita-Pla J; Oliva R; Edel MJ Stem Cells; 2019 Apr; 37(4):476-488. PubMed ID: 30664289 [TBL] [Abstract][Full Text] [Related]
12. iPSC-based treatment of age-related macular degeneration (AMD): The path to success requires more than blind faith. Li F; Hu J; He TC Genes Dis; 2017 Jun; 4(2):41-42. PubMed ID: 30258908 [TBL] [Abstract][Full Text] [Related]
13. The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives. Liu X; Li W; Fu X; Xu Y Front Immunol; 2017; 8():645. PubMed ID: 28626459 [TBL] [Abstract][Full Text] [Related]